CO2023015509A2 - Un método para mejorar la estabilidad de una formulación de anticuerpos - Google Patents
Un método para mejorar la estabilidad de una formulación de anticuerposInfo
- Publication number
- CO2023015509A2 CO2023015509A2 CONC2023/0015509A CO2023015509A CO2023015509A2 CO 2023015509 A2 CO2023015509 A2 CO 2023015509A2 CO 2023015509 A CO2023015509 A CO 2023015509A CO 2023015509 A2 CO2023015509 A2 CO 2023015509A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- formulations
- stability
- improve
- antibody formulation
- Prior art date
Links
- 238000009472 formulation Methods 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 238000001990 intravenous administration Methods 0.000 abstract 1
- 239000012669 liquid formulation Substances 0.000 abstract 1
- 150000002763 monocarboxylic acids Chemical class 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
La presente invención divulga una formulación estable de un anticuerpo α4β7, en la que la formulación comprende un anticuerpo α4β7, un aminoácido, un ácido monocarboxílico o ácido dicarboxílico y un tensioactivo. Las formulaciones de anticuerpos divulgadas son formulaciones líquidas de alta concentración que también son adecuadas para diferentes modos de administración (subcutánea/intravenosa). Las formulaciones divulgadas exhiben estabilidad bajo diversas condiciones de estrés acelerado.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN202141020878 | 2021-05-07 | ||
| PCT/IN2022/050430 WO2022234594A1 (en) | 2021-05-07 | 2022-05-05 | A method of improving stability of an antibody formulation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2023015509A2 true CO2023015509A2 (es) | 2023-11-30 |
Family
ID=83932659
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2023/0015509A CO2023015509A2 (es) | 2021-05-07 | 2023-11-17 | Un método para mejorar la estabilidad de una formulación de anticuerpos |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4333878A1 (es) |
| JP (1) | JP2024516293A (es) |
| CN (1) | CN117545501A (es) |
| AU (1) | AU2022271025A1 (es) |
| BR (1) | BR112023022811A2 (es) |
| CO (1) | CO2023015509A2 (es) |
| WO (1) | WO2022234594A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116466092A (zh) * | 2023-03-21 | 2023-07-21 | 浙江夸克生物科技有限公司 | 定量测定尿视黄醇结合蛋白的试剂盒 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4317010B2 (ja) * | 2001-07-25 | 2009-08-19 | ピーディーエル バイオファーマ，インコーポレイティド | ＩｇＧ抗体の安定な凍結乾燥医薬製剤 |
| JP5231810B2 (ja) * | 2005-12-28 | 2013-07-10 | 中外製薬株式会社 | 抗体含有安定化製剤 |
| UA116189C2 (uk) * | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
-
2022
- 2022-05-05 JP JP2023567976A patent/JP2024516293A/ja active Pending
- 2022-05-05 CN CN202280044125.7A patent/CN117545501A/zh active Pending
- 2022-05-05 EP EP22798790.6A patent/EP4333878A1/en active Pending
- 2022-05-05 AU AU2022271025A patent/AU2022271025A1/en active Pending
- 2022-05-05 WO PCT/IN2022/050430 patent/WO2022234594A1/en active Application Filing
- 2022-05-05 BR BR112023022811A patent/BR112023022811A2/pt unknown
-
2023
- 2023-11-17 CO CONC2023/0015509A patent/CO2023015509A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN117545501A (zh) | 2024-02-09 |
| AU2022271025A1 (en) | 2023-12-14 |
| JP2024516293A (ja) | 2024-04-12 |
| EP4333878A1 (en) | 2024-03-13 |
| BR112023022811A2 (pt) | 2024-01-16 |
| WO2022234594A1 (en) | 2022-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2023015509A2 (es) | Un método para mejorar la estabilidad de una formulación de anticuerpos | |
| JP2017222654A5 (es) | ||
| CO2019011021A2 (es) | Formulacion estable de anticuerpos | |
| ES2635101T3 (es) | Composición suavizante, en particular para textiles, que contiene un agente espesante que contiene un polímero catiónico | |
| AR116753A1 (es) | Proceso de preparación de un derivado de pirazolsulfonilamida | |
| BR112022003169A2 (pt) | Formulações de anticorpo anti-il-23p19 | |
| CU20190015A7 (es) | Formulaciones de anticuerpos inhibidores de masp-2 altamente concentrados, de baja viscosidad y composiciones farmacéuticas que las comprenden | |
| BR112016000563A2 (pt) | Método de preparar uma formulação farmacêutica, método de usar ácido hexanóico e/ou ácido cítrico ou pelo menos um sal dos mesmos, formulação farmacêutica e método de modular ou determinar respostas imunes relacionadas à administração de uma formulação farmacêutica | |
| Lee et al. | Carbomer-based adjuvant elicits CD8 T-cell immunity by inducing a distinct metabolic state in cross-presenting dendritic cells | |
| CO2021017646A2 (es) | Composiciones comprimidas de macitentán, métodos y usos de las mismas | |
| US10463741B2 (en) | Non-gelatin vaccine protectant composition and live attenuated influenza vaccine | |
| CO2021016183A2 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-angptl3 | |
| JP2023078216A (ja) | 化合物の膜透過性を改善するための自己乳化型製剤 | |
| MA43686A (fr) | Formulation liquide stable de gonadotrophines | |
| CO2022000575A2 (es) | Composiciones sólidas que comprenden un derivado de egf(a) y una sal de ácido n-(8-(2-hidroxibenzoil)amino)caprílico | |
| PE20220383A1 (es) | Glicoproteinas sialiladas | |
| PE20211914A1 (es) | Composicion que contiene un acido graso altamente insaturado o ester alquilico del mismo y metodo para producir los mismos | |
| CO2020013552A2 (es) | Formulación de anticuerpos | |
| CN109490550A (zh) | 一种骨钙素检测试剂的校准品及其制备方法 | |
| BR112022020136A2 (pt) | Formulação de anticorpo | |
| BR112022018009A2 (pt) | Composição, método para preparar uma formulação e uso de trietil citrato | |
| AR117707A1 (es) | Formulación de solución de proteínas que contiene una alta concentración de un anticuerpo anti-vegf | |
| CO2022005737A2 (es) | Formulación estable de anticuerpo de integrina | |
| BR112021026492A2 (pt) | Formulações líquidas, formulação liofilizada, artigos de fabricação e método para preparar uma formulação líquida | |
| BR112022019477A2 (pt) | Formulação que contém anticorpo |